Patent ID: 11911447
Assignee: MEDERIS DIABETES LLC
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C  Y | IPC A  C

Claim 0:
1. A peptide selected from Formula II:, Formula II

(SEQ. ID. NO. 1)

aa1-aa2-aa3-aa4-aa5-aa6-aa7-aa8-aa9-aa10-aa11-

 

aa12-aa13-aa14-aa15-aa16-aa17-aa18-aa19-aa20-aa21-

 

aa22-aa23-aa24-aa25-aa26-aa27-aa28-aa29-aa30-aa31-

 

aa32-aa33-aa34-aa35-aa36-aa37-Z

wherein:
Z is OH, N-R4—His, or —NH-R3,
wherein
R3 is H, substituted or unsubstituted C1-C12 alkyl;
R4 is a C2-C10 acyl group, for example Ac or Bz;

aa1 is His, N-R4-His, pGlu-His, or N-R3-His;
aa2 is Aib;
aa3 is Gln or Cit;
aa4 is Gly or D-Ala;
aa5 is Thr or Ser;
aa6 is Phe, Trp, 2FPhe, MePhe, 2FMePhe, or Nal2;
aa7 is Thr or Ser;
aa8 is Ser or Asp;
aa9 is Asp or Glu;
aa10 is Tyr, Leu, Met, Nal2, Bip, or Bip2EtMeO;
aa11 is Ser, Asn, or Bip;
aa12 is Lys, Glu, Ser, or Arg;
aa13 is Tyr, Gln, or Cit;
aa14 is Leu, Met, or Nle;
aa15 is Asp, or Glu;
aa16 is Ser, Gly, Glu, Ala, Aib, Ac5c, Lys, or Arg;
aa17 is Lys;
aa18 is Arg, hArg, Ala, Aib, Ac4c, or Ac5c;
aa19 is Ala, Val, Aib, Ac4c, or Ac5c;
aa20 is Gln, Lys, Arg, Cit, Glu, Aib, Ac4c, or Ac5c;
aa21 is Asp, Glu, Leu, Aib, Ac4c, or Ac5c;
aa22 is Phe, Trp, Nal2, Aib, Ac4c, or Ac5c;
aa23 is Val, Ile, Aib, Ac4c, or Ac5c;
aa24 is Gln, Ala, Glu, or Cit;
aa25 is Trp, or Nal2;
aa26 is Leu;
aa27 is Leu;
aa28 is Gln;
aa29 is Thr, Gly, Aib, Ac4c, or Ac5c;
aa30 is absent or Lys, Aib, Ac4c, Ac5c, or Arg;
aa31 is absent or Arg, Aib, Ac4c, or Ac5c;
aa32 is absent or Asn, Aib, Ac4c, or Ac5c;
aa33 is absent or Arg, Aib, Ac4c, or Ac5c;
aa34 is absent or Asn, Aib, Ac4c, or Ac5c;
aa35 is absent or Asn, Aib, Ac4c, or Ac5c;
aa36 is absent or Ile, Aib, Ac4c, or Ac5C;
aa36 is absent or Ala, Aib, Ac4c, or Ac5C;
aa37 is absent;

wherein any two of aa1-aa36 are optionally cyclized through their side chains to form a lactam linkage.